Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 17,065

Document Document Title
WO/2018/012763A1
The present invention relates to a novel compound and an organic electroluminescent device comprising same. The compound, according to the present invention, can be used in an organic layer, preferably a light-emitting layer, of an organ...  
WO/2018/012780A1
Use of a mixture of compounds according to the present invention as a phosphorescent host material can achieve a high light emitting efficiency and a low driving voltage in an organic electric element. In addition, an organic electric el...  
WO/2018/011160A1
The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis...  
WO/2018/011681A1
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, a...  
WO/2018/012781A1
Provided are an organic electronic element and an electronic device thereof, the organic electronic element being capable of achieving high light-emitting efficiency and a low driving voltage, and can also greatly improve the lifespan of...  
WO/2018/009627A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/006811A1
Disclosed are a substituted imidazolyl compound as shown in formula (I) and a pharmaceutical composition thereof, or a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The compound has a better inhibitory...  
WO/2018/009625A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/009751A1
The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for co...  
WO/2018/002319A1
This invention relates to dihydropyranopynmidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.  
WO/2018/000356A1
The present invention relates to a water-soluble iron ion fluorescent probe, and the fluorescent probe molecule has a structure as shown in the figure below. Also disclosed is a preparation method for the water-soluble iron ion fluoresce...  
WO/2018/004319A2
The present specification relates to a heterocyclic compound of chemical formula 1 and an organic light emitting element comprising the same.  
WO/2018/003962A1
2- (Piperidin-1-yl) pyrimidin-4 (3H) -ones characterized by having a 1,8-diazaspiro [4.5] deca-3-ene, 1-oxa-8-azaspiro [4.5] deca-3-ene, 2,8-diazaspiro [4.5] deca-3-ene, 2-oxa-8-azaspiro [4.5] deca-3-ene, 2,9-diazaspiro [5.5] undeca-3-en...  
WO/2018/005192A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2018/004315A2
The present specification relates to a compound of chemical formula 1 and an organic electronic element comprising the same.  
WO/2018/001948A1
The present invention relates to compounds of formula (I): (I) or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.  
WO/2018/001251A1
Disclosed is a compound for regulating the activity of protein kinases and used for treating or preventing protein kinase-related diseases. In particular, the present invention relates to a benzofuran pyrazole amine protein kinase inhibi...  
WO/2018/004318A2
The present specification relates to a heterocyclic compound of chemical formula 1 and an organic light emitting element comprising the same.  
WO/2018/002219A1
Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)- cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful...  
WO/2017/221999A1
Specifically substituted benzofuro- and benzothienoquinolines and their use in electronic devices, especially electroluminescent devices. When used as charge transport material, charge blocker material and/or host material in electrolumi...  
WO/2017/219917A1
Provided in the present invention is a new method for preparing a trabectedin, using safracin B as the starting material and through a series of reactions synthesizing trabectedin. The method easily obtains raw materials, has fewer synth...  
WO/2017/223280A2
The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.  
WO/2017/218957A1
The present invention provides solid state forms of certain spiro-oxindole compounds, such as funapide and the racemic mixture of funapide and its corresponding (R) enantiomer, pharmaceutical compositions comprising the solid state forms...  
WO/2017/215588A1
Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (1) or a pharmaceutically acceptable salt thereof.  
WO/2017/216686A1
The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for trea...  
WO/2017/216791A1
Provided herein is a conjugate comprising two residues of structurally and/or mechanistically different anticancer bioactive agents, coupled to one another by a biocleavable linking moiety, as well as methods of treating cancer using the...  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/216685A1
The invention provides compounds of Formula (I), wherein R4 and R5 are joined together to form a ring as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, as well as me...  
WO/2017/218920A1
This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.  
WO/2017/216279A1
Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula (I), (II), and (III) structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the...  
WO/2017/218843A1
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof. (Formu...  
WO/2017/211759A1
The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.  
WO/2017/212385A1
Compounds of the general formula : processes for the preparation of these compounds, compositions containing these compounds, and the compounds for use in treating cancer.  
WO/2017/214367A1
The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the me...  
WO/2017/211760A1
The present invention relates to novel antibacterial compounds (1) as defined below, pharmaceutical compositions containing them and their use as antimicrobials. A compound of formula (1): A-L1-Y-L2-R-B, wherein A is a cyclic group havin...  
WO/2017/214423A3
In one aspect, the present disclosure provides analogs of thailanstatin of the formula wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed here...  
WO/2017/213452A1
The present invention relates to a novel 4-(aryl)-N-(3-alkoxyfuro[3,2-b]pyrazin-2-yl)-piperazine-1-ca rboxamide derivative compound useful for prevention or treatment of cancer, a method for preparing the same, and a pharmaceutical compo...  
WO/2017/211303A1
Provided are certain pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as...  
WO/2017/214002A1
The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof a...  
WO/2017/214505A1
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the en...  
WO/2017/209488A1
The present invention relates to a novel compound and an organic electroluminescent device comprising same, the compound, according to the present invention, being used for an organic layer of the organic electroluminescent device, prefe...  
WO/2017/208965A1
The present invention provides an organic compound characterized by being represented by general formula [1] set forth in the claims. In general formula [1], Ar1 and Ar2 are each independently selected from among aryl groups having 6-18 ...  
WO/2017/209155A1
Provided are: a novel sulfonamide compound having ribonucleotide reductase inhibitory activity or a salt thereof; and a pharmaceutical composition which contains this sulfonamide compound or a salt thereof as an active ingredient. A comp...  
WO/2017/210545A1
Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided...  
WO/2017/209265A1
Provided are: a novel compound having P2X7 receptor inhibitory activity; and a pharmaceutical composition having P2X7 receptor inhibitory activity. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In ...  
WO/2017/205425A1
Described herein are molecules for use in organic light emitting diodes comprising at least one moiety A, at least one moiety D, and at least one moiety B.  
WO/2017/202798A1
The present invention provides novel compounds having the general formula (I) wherein R1 to R6, X, Y, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2017/205350A1
Molecular probes for detecting and imaging pancreatic cancer are disclosed. The probes are modified benzoxanthene fluorophores, which are selectively taken up by pancreatic cancer cells, such as pancreatic ductal adenocarcinoma cells. Em...  
WO/2017/200320A1
Provided are: an organic electronic device capable of achieving a high luminous efficiency and a low driving voltage of an organic electronic device and capable of greatly improving the lifespan of a device by using, as a phosphorescent ...  
WO/2017/201134A1
The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.  

Matches 1 - 50 out of 17,065